About us

Bioocus Biotech Limited focuses on the research and development of cellular immunotherapies. Bioocus is not only a leading biotech company in China, but also a whole-value-chain enterprise with self-owned research center, GMP facility, CDMO platform, and technology transferring platform. We have collaborated with renowned universities, research centers, and more than 20 hospitals all over the world.

Innovative Gene Therapy Offers New Hope for Sickle Cell and Thalassemia Patients

BRL-101, represents a groundbreaking advancement in the treatment of sickle cell disease (SCD) through CRISPR/Cas9 gene editing technology. This innovative therapy offers new hope by significantly inc...
Read More
FUCASO: The Revolutionary Fully-Human BCMA CAR-T Therapy with Unmatched Efficacy and Safety

FUCASO is a revolutionary BCMA-targeting CAR-T therapy by IASO BIO, offering unparalleled efficacy and safety for relapsed or refractory multiple myeloma. With high response rates, durable remission, ...
Read More
Optic Nerve Injury-03

Patient: Mrs. Wang Gender: FemaleAge: 42 Nationality:Chinese Diagnosis: Optic Nerve Injury
Read More

Latest News

ANY QUESTIONS FOR US?

For inquiries about our products or price list , please leave your email to us and we will be in touch within 24 hour.

INQUIRY

About us

Popular Products

Innovative Gene Therapy Offers New Hope for Sickle Cell and Thalassemia Patients

FUCASO: The Revolutionary Fully-Human BCMA CAR-T Therapy with Unmatched Efficacy and Safety

Optic Nerve Injury-03

Latest News

Bioocus Advances the Frontier in Treating Pediatric Acute Lymphoblastic Leukemia

Pioneering CAR-T Therapy in B-cell Acute Lymphoblastic Leukemia Shows Unprecedented Efficacy

Innovative CAR-T Cell Therapies Transform Treatment of B Cell Malignancies

ANY QUESTIONS FOR US?